MODERATE-TO-SEVERE ATOPIC DERMATITIS

This study tested a drug called nemolizumab in 109 children aged 2 to 11 with moderate-to-severe eczema. The drug is given as a shot under the skin every 4 weeks for a year. Researchers measured how the drug moves through the body, its safety, and whether it improves eczema sympt…

This study looked at whether nemolizumab, a drug for moderate-to-severe eczema, interferes with the body's ability to respond to tetanus and meningococcal vaccines. 242 adults and teens with eczema received either nemolizumab or a placebo, plus the vaccines. The goal was to see i…

This study tested the drug dupilumab (Dupixent) in 124 adolescents and adults with darker skin tones who have moderate-to-severe eczema. Participants received injections every two weeks for 24 weeks. The goal was to see if the drug safely improves skin symptoms and quality of lif…

This study followed 305 Canadian adults and children (ages 6+) with moderate-to-severe eczema who were prescribed Dupixent as part of their routine care. Researchers measured how many patients achieved at least a 75% reduction in eczema severity after 6, 12, and 18 months. The go…

This study tested a new drug called SHR-1819 in 158 adults with moderate to severe atopic dermatitis (a type of eczema). Participants received one of three doses of the drug or a placebo. The main goal was to see if the drug could reduce eczema severity by at least 75% after 16 w…

This study looked at the long-term safety of the drug SHR-1819 in 79 adults with moderate to severe eczema who had already taken part in earlier studies of the same drug. Researchers tracked side effects and how well the drug controlled the disease over time. The goal was to see …

This study looked at whether rocatinlimab, a drug for moderate-to-severe eczema, changes how well vaccines work. About 221 adults with eczema received either the drug or a placebo, then got tetanus and meningococcal vaccines. The goal was to see if the drug lowers the body's abil…